Gastrointestinal adverse functions were being described with Cagrisema even though they were being moderate to average in depth and diminished after some time. The combination cure was generally effectively tolerated. That said, Cagrilintide remains in Section II/III trials. While the early data is fascinating, it has not yet been authorised https://cagrilintide-structure19741.tinyblogging.com/the-basic-principles-of-cagrilintide-83997955